南财智讯4月17日电，四环医药（00460.HK）发布自愿公告，香港联合交易所于2026年4月16日批准其非全资附属公司轩竹生物科技有限公司（股份代号：02575.HK）实施H股全流通与转换及上市，涉及35724.58万股H股（即3.57亿股）的上市及买卖。该事项尚需待所有其他相关条件达成后方可完成。轩竹生物于2025年在港交所主板上市，聚焦消化、肿瘤及非酒精性脂肪性肝炎等重大疾病领域，具备小分子化药与大分子生物药双研发体系及ADC等多元化产品管线。四环医药作为其控股股东，持续推进“医美+生物制药”双轮驱动战略。本次H股全流通获批有利于提升轩竹生物股份流动性、优化股权结构，并增强集团创新药资产的资本运作能力与市场价值体现。
（文章来源：南方财经网）
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.